0000950170-24-016426.txt : 20240216
0000950170-24-016426.hdr.sgml : 20240216
20240216163034
ACCESSION NUMBER: 0000950170-24-016426
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240214
FILED AS OF DATE: 20240216
DATE AS OF CHANGE: 20240216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ashe Andrew D.
CENTRAL INDEX KEY: 0001573163
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 24648858
MAIL ADDRESS:
STREET 1: C/O DYAX CORP.
STREET 2: 55 NETWORK DRIVE
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
ownership.xml
4
X0508
4
2024-02-14
0001840574
Verve Therapeutics, Inc.
VERV
0001573163
Ashe Andrew D.
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
false
true
false
false
See Remarks
false
Stock Option (right to buy)
12.75
2024-02-14
4
A
false
150000
0
A
2034-02-13
Common Stock
150000
150000
D
Restricted Stock Units
2024-02-14
4
A
false
36000
0
A
Common Stock
36000
36000
D
The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.
President, Chief Operating Officer and General Counsel
/s/ Andrew Ashe
2024-02-16